Immunity & infection

Oral

Testing the in Vivo Efficacy of a Q Fever Vaccine Using a Novel Tri-agonist Compound Library

Wednesday, June 14
6:15 PM - 7:45 PM

Coxiella burnetii is a gram negative, obligate intracellular bacterium that is the causative agent of Q fever, a debilitating disease that can evolve into a fatal chronic infection resulting in endocarditis or neurological manifestations up to 20 years following the initial infection. C. burnetii is designated as a Category B pathogen due to its potential as a robust bioterrorism agent. Despite these facts, the only vaccine that currently exists is licensed in Australia and significant concerns about safety and efficacy necessitate the development of a safer and more effective vaccine. Our research group has developed a novel vaccine adjuvant system by conjugating three Toll-like receptor (TLR) agonists together to form a tri-agonist adjuvant. Using this tri-agonist adjuvant we have developed and tested novel C. burnetii vaccine candidates in vitro and in vivo for safety, immune stimulating activity and protection in a live C. burnetii infection challenge study. We have previously shown that our tri-agonist adjuvants elicit a more balanced Th1 and Th2 immune response and successfully increased antibody scope and diversity compared to non-adjuvanted vaccine candidates, suggesting downstream changes in immune signaling and adaptive immune activation. Here we show that our Q fever vaccination model, formulated with our tri-agonist adjuvant construct, elicits productive and effective adaptive immune responses in both a naïve vaccination model and a live C. burnetti infection. Our studies suggest that our novel C. burnetti vaccine could be an effective and safer alternative to the only vaccine currently available.

Adrienne Gilkes

University of California, Irvine

Presentation(s):

    Send Email for Adrienne Gilkes

    Janine K. Tom

    University of California, Irvine

    Presentation(s):

      Send Email for Janine Tom

      Tyler J. Albin

      University of California, Irvine

      Presentation(s):

        Send Email for Tyler Albin

        Saikat Manna

        University of California, Irvine

        Presentation(s):

          Send Email for Saikat Manna

          Aysegul Nalca

          United States Army Medical Research Institute for Infectious Diseases

          Presentation(s):

            Send Email for Aysegul Nalca

            Huw Davies

            University of California, Irvine

            Presentation(s):

              Send Email for Huw Davies

              Medalyn Supnet

              University of California, Irvine

              Presentation(s):

                Send Email for Medalyn Supnet

                Aarti Jain

                University of California, Irvine

                Presentation(s):

                  Send Email for Aarti Jain

                  Rie Nakajima

                  University of California, Irvine

                  Presentation(s):

                    Send Email for Rie Nakajima

                    Aaron Esser-Kahn

                    University of California, Irvine

                    Presentation(s):

                      Send Email for Aaron Esser-Kahn

                      Phillip L. Felgner

                      University of California, Irvine

                      Presentation(s):

                        Send Email for Phillip Felgner

                        Amanda M. Burkhardt

                        Univeristy of CA-Irvine

                        Presentation(s):

                          Send Email for Amanda Burkhardt


                          Assets

                          Testing the in Vivo Efficacy of a Q Fever Vaccine Using a Novel Tri-agonist Compound Library



                          Attendees who have favorited this

                          Send Email for Testing the in Vivo Efficacy of a Q Fever Vaccine Using a Novel Tri-agonist Compound Library